Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FJMY0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,623
Award facts
- Contract value 100% obligated
- $25,622.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $25,622.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order, awarded on December 5, 2025, with an ultimate completion date of December 29, 2025, was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. EXPAREL is a specialty surgical product used for pain management during and after surgical procedures, consistent with DMS Pharmaceutical Group's established portfolio of advanced pharmaceutical and medical consumables supplied to Department of Defense healthcare facilities.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying indefinite delivery contract, valued at $499,999,999 with a completion date of December 31, 2036, authorizes DLA to issue delivery orders for a comprehensive range of pharmaceuticals and medical consumables to support military healthcare operations globally. DMS Pharmaceutical Group's demonstrated performance across numerous prior delivery orders positions it as a critical supplier within the federal military medical supply chain, capable of fulfilling specialized pharmaceutical requirements across multiple therapeutic categories for Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FJMY0?
SPE2DR26FJMY0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DR26FJMY0 worth?
The government has obligated $25,623 on SPE2DR26FJMY0.
Is contract SPE2DR26FJMY0 an order under another contract?
Yes. SPE2DR26FJMY0 is a delivery order under SPE2DR25D9644, an indefinite delivery contract.
Was contract SPE2DR26FJMY0 competed?
The extent of competition for SPE2DR26FJMY0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award